title: Novel therapeutic agents for cutaneous T-Cell lymphoma.
abstract: Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in the development of new therapies with targeted mechanisms of action and acceptable safety profiles. In this review we focus on such novel strategies that have changed the treatment paradigm of this rare malignancy.
authors.affiliation: NYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY 10016, USA.
authors.forename: Salvia
authors.initials: S
authors.lastname: Jain
authors.forename: Jasmine
authors.initials: J
authors.lastname: Zain
authors.forename: Owen
authors.initials: O
authors.lastname: O'Connor
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000378:metabolism*; D058990:Molecular Targeted Therapy
chemical_list: D000970:Antineoplastic Agents